ArticleMolecules (Basel, Switzerland)2025
Amorphous Fe-Doped Manganese Carbonate for Efficient Activation of Peroxymonosulfate: Mechanism and Performance Toward Orange II Degradation.
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- MnFe aminoclay as a novel catalyst: structural characterization and potential for catechol detection.RSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A novel amorphous Fe-doped manganese carbonate (a-FeMn-1) was synthesized via a facile co-precipitation method and evaluated as an efficient heterogeneous catalyst for the activation of peroxymonosulfate (PMS) in the degradation of Orange II. Among various Fe/Mn molar ratios, the 1:1 composition (a-FeMn-1) showed optimal catalytic activity, achieving 98% removal efficiency within 60 min under near-neutral pH conditions. Characterization results indicated that Fe doping effectively induced an amorphous structure and increased surface area and oxygen defects, promoting PMS activation. The system displayed broad pH applicability and resistance to Cl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.